The Thai Version of the Positive and Negative Syndrome Scale (PANSS) for Schizophrenia: Criterion Validity and Interrater Reliability

Journal of the Medical Association of Thailand

Volumn 83, Issue 6, 2000, Pages 646-651

  Nilchaikovit, Tana ^a   Kessawai, Daranes ^b   Uneanong, Spain ^a   Thomyangkoon, Prakarn ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Negative Symptoms; Positive Symptoms; Schizophrenia

Indexed keywords

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; COMPARATIVE STUDY; EVALUATION; FEMALE; HUMAN; MALE; OBSERVER VARIATION; PATHOPHYSIOLOGY; PSYCHOLOGY; REPRODUCIBILITY; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SYNDROME; THAILAND;

ADULT; BRIEF PSYCHIATRIC RATING SCALE; EVALUATION STUDIES; FEMALE; HUMANS; MALE; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SENSITIVITY AND SPECIFICITY; SYNDROME; THAILAND;

EID: 0347112458     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. WHO. The ICD-10 Classification of mental and behavioral disorders. Geneva: World Health organization, 1993.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition (DSM 4). Washington DC: American Psychiatric Press, 1994.
3. Hughlings-Jackson J. The Selected writings of JH Jackson. London: Hodder and Stoughton, 1931.
4. Kraepelin E, Barclay RM, Robertson GM. Dementia praecox and paraphrenia. Edinburgh: E&S Livingstone 1919.
5. Bleuler E. Dementia Praecox oder die Gruppe der Schizophrenien, Aschaffenburgs Handbuch der Psychiatrie. Leipzig-Wien 1911. Translated into English by H Zinkin. Dementia praecox or the group of schizophrenias. New York: International Universities Press, 1950.
6. Bleuler E. Dementia Praecox oder die Gruppe der Schizophrenien, Aschaffenburgs Handbuch der Psychiatrie. Leipzig-Wien 1911. Translated into English by H Zinkin. Dementia praecox or the group of schizophrenias. New York: International Universities Press, 1950.
7. Schneider K. Psychopathologie, Stuttgart, 1950. Translated into English by MW Hamilton. Clinical Psychopathology. New York: Grune and Stratton, 1959.
8. Schneider K. Psychopathologie, Stuttgart, 1950. Translated into English by MW Hamilton. Clinical Psychopathology. New York: Grune and Stratton, 1959.
9. Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 1980;137:383-6.
10. Andreasen NC, Olson S. Negative versus positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982;39:789-94.
11. Andreasen NC, Flaum M, Swayze VW, Tyrell G, Arndt S. Positive and negative symptoms in schizophrenia. Arch Gen Psychiatry 1990;47:615-21.
12. Lindstrom LH. Clinical and biological markers for outcome in schizophrenia: a review of a lonitudinal follow-up study in Uppsala schizophrenia research project. Neuropsychopharmacology 1996;14:23S-26S.
13. Arndt S, Andreasen NC, Flaum M, Miller D, Nopoulos P. A longitudinal study of symptom dimensions in schizophrenia: prediction and pattern of change. Arch Gen Psychiatry 1995;52: 341-51.
14. Meltzer HY, Sommers AA, Luchins DJ. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 1986;6:329-38.
15. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
16. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-6.
17. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
18. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151: 825-35.
19. Tollefson GD, Sanger TM. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-74.
20. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-91.
21. Carpenter Jr. WT. Serotonin-Dopamine antagonists and treatment of negative symptoms. J Clin Psychopharmacol 1995;15:30S-5S.
22. Rao ML, Moller HJ. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. Neuropsychobiology 1994; 30:160-72.
23. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
24. Overall JE, Gorham DR. Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
25. Singh MM, Kay SR. A comparative study of haloperidol and chlorpromazine in term of clinical effects and therapeutic reversal with benztropine in schizophrenia: theoretical implications for potency differences among neuroleplics. Psychopharmacologia 1975;43:103-13.
26. Kay SR. Positive and negative syndromes in schizophrenia: Assessment and research. New York: Brunner/Mazel, 1991.
27. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) rating manual. North Tonawanda, New York: Multi-Health Systems, Inc., 1986.
28. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988;23: 99-110.